Avadel Pharmaceuticals plc (NASDAQ:AVDL) does about 1.24M shares in volume on a normal day but saw 1332519 shares change hands in Friday trading. The company now has a market cap of 1.65B USD. Its current market price is $17.33, marking a decrease of -0.29% compared to the previous close of $17.38. The 52 week high reached by this stock is $18.85 whilst the lowest price level in 52 weeks is $9.50.
Avadel Pharmaceuticals plc (AVDL) has a 20-day trading average at $16.81 and the current price is -8.06% off the 52-week high compared with 82.42% distance from its 52-week low. The 50-day simple moving average of the closing price is $15.56 and its 200-day simple moving average is $13.57. If we look at the stock’s price movements over the week, volatility stands at 9.15%, which decreases to 5.52% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 57.83 to suggest the stock is neutral.
The consensus objective for the share price is $22.90, suggesting that the stock has a potential upside of 24.32% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on March 05, 2024 when Oppenheimer reiterated the stock to “Outperform” and issued a price target of between $27 and $29. H.C. Wainwright reiterated its price target at $21-$25.
Avadel Pharmaceuticals plc (AVDL) stock is up 8.38% over the week and 4.59% over the past month. Its price is 22.73% year-to-date and 70.91% over the past year.
The stock last released its quarterly earnings report for quarter ended 12/31/2023, with the company’s earnings per share (EPS) of -$0.29 below consensus estimates by -$0.03. AVDL’s earnings per share are forecast to grow by 80.00% this year and 355.00% over next year. Expected sales for next quarter are $36.61 million, which analysts say will come at $162.18 million for the current fiscal year and next year at $291.9 million. In addition, estimates put the company’s current quarterly revenue at an average of $26.67 million.
To reach the target analysts have set, the stock logically needs to grow 24.32 percent from here.
The company has a return on investment of -131.17% and return on equity of -481.35%. The forward price to earnings ratio is 22.31. The beta has a value of 1.61. Price to book ratio is 18.78 and price to sales ratio is 58.89.
